Persistence with bisphosphonate therapy including treatment courses with multiple sequential bisphosphonates in the real world

[1]  G. Oster,et al.  Compliance with drug therapy for postmenopausal osteoporosis , 2006, Osteoporosis International.

[2]  D. Gold,et al.  How Can Osteoporosis Patients Benefit More from Their Therapy? Adherence Issues with Bisphosphonate Therapy , 2006, The Annals of pharmacotherapy.

[3]  A. Westfall,et al.  Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users , 2006, Osteoporosis International.

[4]  J. Cramer,et al.  Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. , 2006, The American journal of medicine.

[5]  M. Ettinger,et al.  Improving compliance and persistence with bisphosphonate therapy for osteoporosis. , 2006, The American journal of medicine.

[6]  S. Giannini,et al.  Determinants of adherence to osteoporosis treatment in clinical practice , 2006, Osteoporosis International.

[7]  H. Naito.  The Japanese Health-Care System and Reimbursement for Dialysis , 2006, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[8]  R. Herings,et al.  Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. , 2006, Clinical therapeutics.

[9]  Masahiro Yoshida,et al.  Health insurance system and payments provided to patients for the management of severe acute pancreatitis in Japan , 2006, Journal of hepato-biliary-pancreatic surgery.

[10]  A. Westfall,et al.  Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. , 2005, Arthritis and rheumatism.

[11]  J. Árnason,et al.  Correlation between patient recall of bone densitometry results and subsequent treatment adherence , 2005, Osteoporosis International.

[12]  J. Rodriguez-Portales,et al.  Ten years' experience with alendronate for osteoporosis in postmenopausal women. , 2004, The New England journal of medicine.

[13]  J. Mccombs,et al.  Compliance with drug therapies for the treatment and prevention of osteoporosis. , 2003, Maturitas.

[14]  Jacques P. Brown,et al.  Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database , 2003, Osteoporosis International.

[15]  B. Ettinger,et al.  Early discontinuation of treatment for osteoporosis. , 2003, The American journal of medicine.

[16]  K. McCoy,et al.  Tolerability and compliance with risedronate in clinical practice , 2003, Osteoporosis International.

[17]  Y. Taketani,et al.  A Comparison of the Effect of Risedronate and Etidronate on Lumbar Bone Mineral Density in Japanese Patients with Osteoporosis: A Randomized Controlled Trial , 2002, Osteoporosis International.

[18]  D. Bauer,et al.  Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? , 2002, Mayo Clinic proceedings.

[19]  Gordon Guyatt,et al.  Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. , 2002, Endocrine reviews.

[20]  G. Guyatt,et al.  Meta-Analyses of Therapies for Postmenopausal Osteoporosis , 2002 .

[21]  M. McClung.  Bisphosphonates in osteoporosis: recent clinical experience , 2000, Expert opinion on pharmacotherapy.

[22]  M. Cedars,et al.  A medication use evaluation of alendronate: compliance with administration guidelines. , 1999, Pharmacy practice management quarterly.